Receptor, erbB-2
Research News and Information

Sunday, November 22, 2009

A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.

21 Oct 2009 A workshop sponsored by the National Cancer Institute and the US Food and Drug Administration addressed past lessons learned and ongoing challenges faced in biomarker development and drug and biomarker codevelopment. Participants agreed that ... Read more...

Amplification and expression of EGFR and ERBB2 in Wilms tumor.

13 Oct 2009 Wilms tumor is one of the most common solid tumors in children. We evaluated expression and amplification of a number of genes and their prognostic significance in 45 patients with Wilms tumor, using tissue microarray technology. The expression of ... Read more...

Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer.

13 Oct 2009 Hepatitis B x antigen, or HBxAg, contributes importantly to the pathogenesis of hepatocellular carcinoma (HCC). Given that HBxAg constitutively activates beta-catenin and that upregulated ErbB-2 promotes beta-catenin signaling in other tumor types, ... Read more...

Latest indexed articles for 'Receptor, erbB-2'

These are the very latest articles for this heading:

• HER2 Intermediate Breast Cancers. 30 Oct 2009
• A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. 21 Oct 2009
• Amplification and expression of EGFR and ERBB2 in Wilms tumor. 13 Oct 2009
• Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. 13 Oct 2009
• Parity and age at first childbirth in relation to the risk of different breast cancer subgroups. 13 Oct 2009
• A modular platform for the rapid site-specific radiolabeling of proteins with 18F exemplified by quantitative positron emission tomography of human epidermal growth factor receptor 2. 6 Oct 2009
• Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. 4 Oct 2009
• Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? 29 Sep 2009
• [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status] 29 Sep 2009
• HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. 29 Sep 2009
• Emerging technologies for assessing HER2 amplification. 29 Sep 2009
• Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH. 29 Sep 2009
• Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. 29 Sep 2009
• Bidirectional signaling of ErbB and Eph receptors at synapses. 27 Sep 2009
• Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. 27 Sep 2009
• Gene expression of circulating tumour cells in breast cancer patients. 26 Sep 2009
• EGFR and HER2 expression in advanced biliary tract cancer. 26 Sep 2009
• Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. 19 Sep 2009
• The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. 16 Sep 2009
• Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma. 13 Sep 2009

See a longer list of these articles.

Technical information about 'Receptor, erbB-2'

Definition: A cell surface protein-tyrosine kinase receptor that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor (RECEPTOR, EPIDERMAL GROWTH FACTOR), the erbB-3 receptor (RECEPTOR, ERBB-3) and the erbB-4 receptor. Activation of the erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB receptor family members.

Registry Number: EC 2.7.1.112

Descriptor UI: D018719

Alternative terms: Receptor, erbB-2; Receptor, erbB 2; erbB-2 Receptor; neu Receptor; Proto-Oncogene Protein p185(neu); Proto-Oncogene Proteins c-erbB-2; Proto Oncogene Proteins c erbB 2; p185(c-neu); Receptors, erbB-2; Receptors, erbB 2; erbB-2 Receptors; erbB-2 Proto-Oncogene Protein; Proto-Oncogene Protein, erbB-2; erbB 2 Proto Oncogene Protein; erbB-2 Receptor Protein-Tyrosine Kinase; erbB 2 Receptor Protein Tyrosine Kinase; neu Proto-Oncogene Protein; Proto-Oncogene Protein, neu; neu Proto Oncogene Protein; HER-2 Proto-Oncogene Protein; HER 2 Proto Oncogene Protein; Proto-Oncogene Protein, HER-2; Proto-Oncogene Protein HER-2; Proto Oncogene Protein HER 2; Receptor, neu; Oncogene Protein HER-2; Oncogene Protein HER 2; c-erbB-2 Protein; c erbB 2 Protein;

Related Mesh Headings: Genes, erbB-2;

Allowable Qualifiers: administration & dosage; analysis; antagonists & inhibitors; biosynthesis; blood; classification; deficiency; drug effects; genetics; history; immunology; isolation & purification; metabolism; physiology; radiation effects; therapeutic use; ultrastructure; chemistry; agonists;

Tree Number: D08.811.913.696.620.682.725.400.150; D12.776.543.750.060.374; D12.776.543.750.750.400.350; D12.776.624.664.700.642; D23.101.840.642;

History Note: 2000(1995); use RECEPTOR, ERBB-2 (NM) 1985-1994